Lifeng Yu

971 total citations · 2 hit papers
23 papers, 594 citations indexed

About

Lifeng Yu is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Lifeng Yu has authored 23 papers receiving a total of 594 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 8 papers in Oncology and 6 papers in Immunology. Recurrent topics in Lifeng Yu's work include Ferroptosis and cancer prognosis (4 papers), Ion channel regulation and function (4 papers) and Cardiac electrophysiology and arrhythmias (4 papers). Lifeng Yu is often cited by papers focused on Ferroptosis and cancer prognosis (4 papers), Ion channel regulation and function (4 papers) and Cardiac electrophysiology and arrhythmias (4 papers). Lifeng Yu collaborates with scholars based in China, Japan and United States. Lifeng Yu's co-authors include Minjie Wei, Lin Zhao, Zhaojin Yu, Chen Fu, Yuxi Miao, Longyang Jiang, Minjie Wei, Xinli Liu, Zinan Li and Yan Wang and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, Frontiers in Immunology and American Journal of Physiology-Cell Physiology.

In The Last Decade

Lifeng Yu

22 papers receiving 588 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?

2022 133 citations Chen Fu, Lifeng Yu et al. Acta Pharmaceutica Sinica B profile →
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals

2025 33 citations Ruili Wang, Chen Mo et al. Journal of Hematology & Oncology profile →

Peers

Countries citing papers authored by Lifeng Yu

Since Specialization

Citations

This map shows the geographic impact of Lifeng Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lifeng Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lifeng Yu more than expected).

Fields of papers citing papers by Lifeng Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lifeng Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lifeng Yu. The network helps show where Lifeng Yu may publish in the future.

Co-authorship network of co-authors of Lifeng Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Lifeng Yu. A scholar is included among the top collaborators of Lifeng Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lifeng Yu. Lifeng Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals breakdown → 2025 ·Journal of Hematology & Oncology ·Ruili Wang, (unknown), (unknown), Chen Mo, Xin Zhao, (unknown), Ping Hou, Qi Cui, Xu Zhao, Wenjia Wang, Zhaojin Yu, Lin Zhao, Miao He, Yan Wang, Chen Fu, Minjie Wei, Lifeng Yu	33
2	When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside? 2024 ·Pharmacological Research ·Chen Fu, Weiwei Tong, Lifeng Yu, Yuxi Miao, Qian Wei, Zhaojin Yu, Qing Chen, Minjie Wei	21
3	Advances of research of Fc-fusion protein that activate NK cells for tumor immunotherapy 2022 ·International Immunopharmacology ·(unknown), (unknown), Lifeng Yu, Yongping Lu, Yan Wang, (unknown), (unknown), Jianing Li, (unknown), Xinyue Song, Xinyu Wang, Jiaqi Wang, (unknown), (unknown), Zhaojin Yu, Lin Zhao, (unknown), Minjie Wei	8
4	Computational Recognition of a Regulatory T-cell-specific Signature With Potential Implications in Prognosis, Immunotherapy, and Therapeutic Resistance of Prostate Cancer 2022 ·Frontiers in Immunology ·Mingyi Ju, Jingyi Fan, (unknown), (unknown), Longyang Jiang, Wei Qian, Jia Bi, (unknown), Qiutong Guan, Xinyue Song, Mingyan Dong, Lin Wang, Lifeng Yu, Yan Wang, Hui Kang, (unknown), Lin Zhao	7
5	Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope? breakdown → 2022 ·Acta Pharmaceutica Sinica B ·Chen Fu, Lifeng Yu, Yuxi Miao, Xinli Liu, Zhaojin Yu, Minjie Wei	133
6	Basal Ganglia Calcification Is Associated With Local and Systemic Metabolic Mechanisms in Adult Hypoparathyroidism 2021 ·The Journal of Clinical Endocrinology & Metabolism ·Guido Zavatta, Peter J. Tebben, Cynthia H. McCollough, Lifeng Yu, Thomas J. Vrieze, B.L. Clarke	12
7	Overexpression of PTPRN Promotes Metastasis of Lung Adenocarcinoma and Suppresses NK Cell Cytotoxicity 2021 ·Frontiers in Cell and Developmental Biology ·Xinyue Song, Xue Jiao, Yan Han, Lifeng Yu, Longyang Jiang, Ming Zhang, (unknown), Mingyi Ju, Lin Wang, Qian Wei, Lin Zhao, Minjie Wei	15
8	A Immune-Related Signature Associated with TME Can Serve as a Potential Biomarker for Survival and Sorafenib Resistance in Liver Cancer 2021 ·OncoTargets and Therapy ·Mingyi Ju, Longyang Jiang, Wei Qian, Lifeng Yu, (unknown), Yan Wang, (unknown), Ping Qian, (unknown), Chenyi Zhou, Zinan Li, Minjie Wei, Lin Zhao, Jiali Han	13
9	BRAF and KRAS mutations in metastatic colorectal cancer: future perspectives for personalized therapy 2020 ·Gastroenterology report ·Zinan Li, Lin Zhao, Lifeng Yu, Minjie Wei	77
10	Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response 2019 ·Cell Death and Disease ·(unknown), Lifeng Yu, Xinyue Song, Jia Bi, Longyang Jiang, Yan Wang, Miao He, Qinghuan Xiao, Mingli Sun, Olufunmilayo I. Olopade, Lin Zhao, Minjie Wei	22
11	Identification of a novel cell cycle‐related gene signature predicting survival in patients with gastric cancer 2018 ·Journal of Cellular Physiology ·(unknown), (unknown), Longyang Jiang, (unknown), Qian Wei, Jia Bi, Yan Wang, Lifeng Yu, Miao He, (unknown), (unknown), Minjie Wei	58
12	High PITX1 expression in lung adenocarcinoma patients is associated with DNA methylation and poor prognosis 2018 ·Pathology - Research and Practice ·Xinyue Song, Chaoran Zhao, Longyang Jiang, (unknown), Jia Bi, Qian Wei, Lifeng Yu, Lin Zhao, Minjie Wei	24
13	Moesin is an independent prognostic marker for ER‑positive breast cancer 2018 ·Oncology Letters ·Lifeng Yu, Lin Zhao, Huizhe Wu, Haishan Zhao, Zhaojin Yu, Miao He, Feng Jin, Minjie Wei	17
14	MFG-E8 overexpression is associated with poor prognosis in breast cancer patients 2018 ·Pathology - Research and Practice ·Lifeng Yu, Lin Zhao, (unknown), Jia Bi, Qian Wei, Xinyue Song, Longyang Jiang, (unknown), Minjie Wei	10
15	Prognostic value of miRNA-181a in human colorectal cancer evaluated by in situ hybridization 2018 ·Translational Cancer Research ·Shu Lin, Lin Zhao, Xinyue Song, Jing Zhang, Yan Wang, Longyang Jiang, Lifeng Yu, (unknown), Minjie Wei	2
16	MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1) 2016 ·Journal of Experimental & Clinical Cancer Research ·Lin Zhao, Yan Wang, Longyang Jiang, Miao He, Xuefeng Bai, Lifeng Yu, Minjie Wei	73
17	Electrophysiological effect and the gating mechanism of astragaloside IV on l-type Ca2+ channels of guinea-pig ventricular myocytes 2015 ·European Journal of Pharmacology ·Meimi Zhao, (unknown), Lifeng Yu, Xuefei Sun, Yan Wang, Huiyuan Hu, Rui Feng, Qinghua Gao, Feng Guo, Liying Hao	7
18	PKA and phosphatases attached to the Ca_V1.2 channel regulate channel activity in cell-free patches 2015 ·American Journal of Physiology-Cell Physiology ·Jianjun Xu, Lifeng Yu, Etsuko Minobe, Liting Lu, Ming Lei, Masaki Kameyama	10
19	Adenosine triphosphate regulates the activity of guinea pig Cav1.2 channel by direct binding to the channel in a dose-dependent manner 2014 ·American Journal of Physiology-Cell Physiology ·Rui Feng, Jianjun Xu, Etsuko Minobe, Asako Kameyama, Lei Yang, Lifeng Yu, Liying Hao, Masaki Kameyama	11
20	Mechanisms underlying the modulation of L-type Ca2+ channel by hydrogen peroxide in guinea pig ventricular myocytes 2013 ·The Journal of Physiological Sciences ·Lei Yang, Jianjun Xu, Etsuko Minobe, Lifeng Yu, Rui Feng, Asako Kameyama, Kazuto Yazawa, Masaki Kameyama	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact